Cell Line and Reporter Gene Effects in mRNA-LNP Transfection Assays

Study Background and Research Question

Messenger RNA (mRNA) lipid nanoparticles (LNPs) have become a central platform for vaccine and therapeutic development, as demonstrated by their pivotal role in COVID-19 vaccines. The ability to optimize mRNA-LNP formulations in vitro is essential for advancing gene therapy and vaccine research. However, there has been limited systematic evaluation of how cell line characteristics and reporter gene selection impact the assessment of mRNA-LNP transfection efficiency. Zhen et al. (2025) address this gap by studying the influence of both variables on in vitro readouts, aiming to clarify the reliability and reproducibility of commonly used reporter assays in different cellular models.

Key Innovation from the Reference Study

The main innovation of the study is its comparative approach: Zhen et al. evaluate multiple cell lines—Jurkat (suspension), L-929 (adherent fibroblast), and HEK 293T (adherent epithelial)—and two reporter genes (firefly luciferase and eGFP) in the context of mRNA-LNP transfection. By systematically quantifying both bioluminescent and fluorescent reporter outputs, the authors identify critical assay parameters that influence the interpretation of transfection efficiency and protein expression data. This work provides empirical evidence that both the cell line and reporter gene choice can substantially affect assay sensitivity, linearity, and reproducibility, which are crucial for mRNA delivery and transfection optimization workflows.

Methods and Experimental Design Insights

The experimental protocol involved preparing mRNA-LNP complexes encoding either firefly luciferase or eGFP and transfecting them into three cell lines with distinct biological properties. The study monitored reporter expression by measuring bioluminescence (for luciferase) and fluorescence (for eGFP) at various mRNA doses. Technical replicates and dose-response analyses were employed to assess both the linearity and variability of reporter outputs. Importantly, the study also evaluated cytotoxicity and background signal, providing a comprehensive view of assay performance across platforms.

Protocol Parameters

• Cell line selection: Jurkat (human T-cell leukemia, suspension), L-929 (mouse fibroblast, adherent), HEK 293T (human embryonic kidney, adherent).
• Reporter gene constructs: Firefly luciferase mRNA and eGFP mRNA, both delivered via LNPs.
• Dose-response evaluation: Multiple mRNA concentrations assessed to determine signal linearity and dynamic range.
• Assessment endpoints: Bioluminescence (luciferase activity), fluorescence (eGFP), cytotoxicity, and intra-group variability.

Core Findings and Why They Matter

The study revealed several important findings:

• Jurkat cells displayed low transfection efficiency and a non-linear response to increasing luciferase mRNA doses. Even low mRNA concentrations were associated with cytotoxicity, limiting their utility for quantitative assays.
• L-929 cells showed a linear relationship between mRNA concentration and luciferase-generated bioluminescence, but only at low mRNA doses. The maximum signal was limited, and higher concentrations did not increase expression proportionally.
• HEK 293T cells outperformed other lines, exhibiting a strong linear dose-response and higher signal intensity for luciferase expression. However, luciferase-based assays in HEK 293T cells displayed significant intra-group variation, reducing reliability for comparative studies.
• eGFP mRNA as a reporter offered superior reproducibility, with a coefficient of variation below 10% and a robust linear correlation (R² > 0.95) between mRNA dose and fluorescence output across cell lines.

These findings underscore the importance of considering both cell model and reporter system when designing mRNA delivery and translation efficiency assays. For example, the enhanced reproducibility and linearity seen with eGFP suggest that fluorescent reporters may be preferable for high-throughput screening and quantitative benchmarking of mRNA-LNP formulations, while bioluminescent reporters may be more sensitive but less robust to technical variation (Zhen et al., 2025).

Comparison with Existing Internal Articles

The findings from Zhen et al. are complemented by several recent studies on mRNA delivery systems. For instance, a comparative analysis of PEGylated mRNA polyplexes demonstrated that optimized PEG ratios could enhance colloidal stability without compromising transfection efficiency, which is relevant for selecting robust delivery platforms (see PEGylation study). Shimizu and Hattori's work on lyophilized mRNA lipoplexes further highlights how formulation parameters such as disaccharide and lipid composition can influence both stability and transfection efficiency, aligning with the need for systematic optimization across assay components (see disaccharide/lipid effects).

Furthermore, several resources detail the use of Cap1-capped, 5-moUTP-modified, and Cy5-labeled mRNAs as dual-mode reporters for mRNA delivery tracking and translation efficiency assays. These advanced reagents offer improved stability, reduced innate immune activation, and the possibility for both fluorescence-based and bioluminescence-based readouts, providing a bridge between the strengths and limitations observed in the Zhen et al. study (EZ Cap Cy5 Firefly Luciferase mRNA).

Limitations and Transferability

While the study offers valuable guidance, several limitations should be considered:

• Cell type diversity: The selected cell lines are widely used but do not encompass the full range of primary or specialized cells relevant to mRNA-LNP therapeutic applications.
• Reporter gene context: The non-linear or variable responses observed may not generalize to all reporter systems or assay formats, particularly for in vivo bioluminescence imaging or translation efficiency assays in complex tissues.
• Assay readout limitations: Bioluminescent signals can be affected by substrate availability and cellular ATP levels, potentially confounding interpretation, while fluorescent readouts may be influenced by cellular autofluorescence or quenching effects.

Given these factors, researchers should carefully validate their choice of cell line and reporter system for their specific application, especially when translating in vitro findings to in vivo or clinical settings.

Why this cross-domain matters, maturity, and limitations

The issues of assay reproducibility and sensitivity raised here extend beyond basic research, affecting the maturity and translational potential of mRNA therapeutics. Reliable in vitro models are foundational for screening mRNA-LNP candidates not only for vaccines but also for protein replacement and gene editing applications. However, direct extrapolation to in vivo efficacy must consider additional variables such as immune activation and biodistribution, which may not be fully captured by current in vitro assay systems.

Research Support Resources

To support robust mRNA delivery and transfection studies, researchers may benefit from using dual-reporter mRNA reagents that combine the advantages of both bioluminescent and fluorescent detection. Products such as EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) offer a Cap1 structure and 5-moUTP modification to enhance translation efficiency and stability, while Cy5 labeling allows direct visualization of mRNA uptake and intracellular trafficking. Such reagents enable comprehensive evaluation of mRNA delivery, translation, and immune response, aligning with the methodological recommendations from Zhen et al.